The FDA on August 16, 2019 approved INREBICĀ® for adults with intermediate-2 or high-risk Primary or Secondary (post-Polycythemia Vera or post-Essential Thrombocythemia) Myelofibrosis (MF). INREBICĀ® is a product of Impact Biomedicines, Inc.
Other Pages – Bottom Ad
Advertisement
Subscribe
